Credit Suisse Downgrades Omnicare To Neutral

Analysts at Credit Suisse downgraded

from Outperform to Neutral. The price target for Omnicare has been raised from $85.00 to $91.00. Omnicare shares have gained 43.45 percent over the past 52 weeks, while the S&P 500 index has surged 12.21 percent in the same period. Omnicare's shares rose 4.26 percent to close at $84.52 yesterday.